HC Wainwright Reiterates Buy Rating for Mural Oncology (NASDAQ:MURA)

Mural Oncology (NASDAQ:MURA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 391.80% from the stock’s current price.

Mural Oncology Stock Down 1.9 %

NASDAQ MURA opened at $3.66 on Wednesday. The company has a 50-day moving average price of $3.85 and a 200-day moving average price of $3.58. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.23. The firm has a market capitalization of $62.29 million, a P/E ratio of -0.40 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the previous year, the company earned ($3.57) earnings per share. As a group, equities research analysts anticipate that Mural Oncology will post -7.54 EPS for the current year.

Hedge Funds Weigh In On Mural Oncology

Several large investors have recently made changes to their positions in the business. Commerce Bank bought a new stake in Mural Oncology during the 3rd quarter valued at approximately $39,000. FMR LLC raised its position in shares of Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Mural Oncology in the fourth quarter worth $68,000. Two Sigma Advisers LP bought a new position in shares of Mural Oncology during the fourth quarter worth $84,000. Finally, Bridgeway Capital Management LLC purchased a new position in Mural Oncology during the fourth quarter valued at $94,000. 80.21% of the stock is currently owned by hedge funds and other institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.